July 21, 2024
You are here:  Home  >  Health Care & Life Science  >  Current Article

Amgen sees blockbuster potential in new cancer drug


For the past year, Amgen has been touting its latest drug, Lumakras, a treatment for non-small cell lung cancer and a particular genetic mutation called KRAS G12C, as its next big blockbuster. A few days ago, the Thousand Oaks-based biotech company got a new sign that its ambitions for Lumakras might prove true. On Sept.…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.